NeuroKappa Therapeutics

Executive Summary

NeuroKappa Therapeutics is a private biopharmaceutical company founded in 2020 and headquartered in San Diego, CA, focused on developing small molecule therapeutics targeting the kappa opioid receptor (KOR). The company’s name reflects its core mission: leveraging KOR modulation for a range of central nervous system disorders, including stroke, pain management, depression, and addiction. By targeting the KOR pathway, NeuroKappa aims to address significant unmet medical needs in neurology and psychiatry, building on the known pharmacology of KOR agonists and antagonists in conditions such as opioid overdose (e.g., naloxone) and beyond. As a preclinical-stage company, NeuroKappa is positioned to advance novel compounds that may offer improved efficacy and safety profiles compared to existing treatments. The company’s private status and lack of disclosed funding rounds suggest it is in early development, likely with lead optimization or IND-enabling studies underway. While the KOR target is validated in clinical settings for certain indications, achieving differentiation and demonstrating favorable risk-benefit will be critical for NeuroKappa’s success. The absence of publicly available pipeline details limits visibility into specific programs, but the company’s concentration on a well-characterized receptor provides a solid scientific foundation for future clinical development.

Upcoming Catalysts (preview)

• TBDLead candidate nomination for a KOR agonist program (e.g., stroke or pain)30% success
• TBDIND filing for a first-in-class KOR-targeting therapeutic20% success
• TBDPartnership or licensing deal to advance KOR antagonist for addiction or depression25% success